For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of anti-infectives and oncology.

Read more

For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of anti-infectives and oncology.

Read more

For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of anti-infectives and oncology.

Read more

We are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

CEO David Veitch | Half-year 2022

Play

Half-Year Report 2022

Download English
Download German

Report Archive

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. Based on our proven expertise in advancing anti-infectives through research and development to the market, we are aiming at becoming one of the leading companies in this space.